Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cgh.2024.09.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Oxalate Esophagitis.
Clin Gastroenterol Hepatol
October 2024
Pathology Department, Hotel Dieu de France Hospital, Saint Joseph University, Beirut, Lebanon.
Immune microenvironment modulation following neoadjuvant therapy for oesophageal adenocarcinoma: a translational analysis of the DEBIOC clinical trial.
ESMO Open
November 2024
Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast. Electronic address:
Article Synopsis
- - The DEBIOC trial explored the safety and efficacy of neoadjuvant treatment using oxaliplatin and capecitabine (Xelox) with or without AZD8931 in patients with oesophageal adenocarcinoma, showing moderate safety but limited effectiveness.
- - Researchers analyzed genetic data from 25 pre-treatment and 18 post-treatment biopsy samples to examine how these treatments influenced biological pathways related to cancer through advanced software tools.
- - Their findings identified three molecular subgroups linked to immune response, with treatment affecting immune signaling and tumor-infiltrating lymphocytes, while the addition of AZD8931 promoted a less favorable immunosuppressive environment and common cancer resistance mechanisms.
Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.
J Clin Oncol
July 2024
Henan Key Laboratory of Microbiome and Esophageal Cancer Prevention and Treatment, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital (College of Clinical Medicine) of Henan University of Science and Technology, Luoyang, China.
Purpose: This phase 3 trial aimed to compare the efficacy and safety of capecitabine or capecitabine plus oxaliplatin (XELOX) with those of fluorouracil plus cisplatin (PF) in definitive concurrent chemoradiotherapy (DCRT) for inoperable locally advanced esophageal squamous cell carcinoma (ESCC).
Methods: Patients were randomly assigned to receive two cycles of capecitabine, XELOX, or PF along with concurrent intensity-modulated radiation therapy. Patients in each arm were again randomly assigned to receive two cycles of consolidation chemotherapy or not.
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPLORING study).
Front Immunol
December 2023
Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Background: The efficacy of current adjuvant chemotherapy for gastric adenocarcinoma/gastroesophageal junction adenocarcinoma (GA/GEJA) leaves much to be desired. ctDNA could serve as a potential marker to identify patients who are at higher risk of recurrence. Reinforcing standard adjuvant chemotherapy with immunotherapy has already been indicated to significantly improve clinical outcome, albeit such evidence is rare in GA/GEJA.
View Article and Find Full Text PDFIncreased abundance of bacteria of the family Muribaculaceae achieved by fecal microbiome transplantation correlates with the inhibition of kidney calcium oxalate stone deposition in experimental rats.
Front Cell Infect Microbiol
June 2023
Department of Urology, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan, Hubei, China.
Background: The incidence of nephrolithiasis is increasing rapidly worldwide. Calcium oxalate is the most common constituent, contributing to approximately 80% of all kidney stones. The gut microbiome, through its oxalate-degrading ability, may play a role in decreasing morbidity due to urinary calculus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!